Direct-to-Consumer Campaigns Phathom Pharmaceuticals has successfully launched multiple direct-to-consumer campaigns for their GI disease treatments, indicating a strong consumer interest and potential sales growth opportunities through increased awareness and engagement.

Meaningful Broadcast Advertising The recent full-scale broadcast ad launch by Phathom Pharmaceuticals showcases their commitment to impactful marketing strategies, providing a platform for sales teams to capitalize on the increased brand visibility and market presence.

New Telehealth Features With the introduction of telehealth features in their marketing initiatives, Phathom Pharmaceuticals has adapted to evolving consumer preferences, presenting sales teams with opportunities to leverage virtual engagement and facilitate customer access to their products.

Product Expansion Initiatives Phathom Pharmaceuticals' expansion into new treatment options like Non-Erosive GERD with vonoprazan NDA submission signifies a proactive approach towards product diversification, offering sales representatives a broader portfolio to address varying customer needs and preferences.

Revenue and Funding Growth Based on the company's revenue of $10M - $50M and funding of $150M, Phathom Pharmaceuticals demonstrates financial stability and potential for further sales expansion, providing sales development representatives with a solid foundation for pursuing new market opportunities and partnerships.